How do breast cancer clinical trials approach cardiovascular safety: targeted or generalized?
- Resource Type
- article
- Authors
- Arsalan Hamid; Gregg C. Fonarow; Javed Butler; Michael E. Hall
- Source
- Cardio-Oncology, Vol 10, Iss 1, Pp 1-5 (2024)
- Subject
- Breast cancer
Clinical trials
Cardiovascular safety
Prevent cardiotoxicity
Diseases of the circulatory (Cardiovascular) system
RC666-701
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
- Language
- English
- ISSN
- 2057-3804
Abstract Background Different breast cancer pharmacotherapy agents cause different forms of cardiovascular toxicity. We aim to assess if breast cancer pharmacotherapy trials approach cardiovascular safety in a targeted or generalized manner when administering different agents. Methods We searched Embase and Medline for phase 2 and 3 breast cancer pharmacotherapy trials. We examined exclusion criterion for cardiovascular conditions and cardiovascular safety assessment through cardiovascular imaging, electrocardiogram, troponin, or natriuretic peptides. Fisher’s exact test was utilized to compare reporting. Results Fifty breast cancer clinical trials were included in this study. Trials administering microtubule inhibitors were most likely to exclude patients with any CV condition compared with trials administering other agents (93.5% vs. 68.4%; p